Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SLC9A3 | P48764 | 7/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730754 | 0.86 | HDAC1 (0.40) | — | |
| SCHEMBL997019 | 0.83 | HTR6 (0.40) | MAPTALDH1A1SLC9A3HTTL3MBTL1 | |
| SCHEMBL18950705 | 0.83 | MAPT (0.43) | MAPTALDH1A1SLC9A3HTTL3MBTL1 | |
| SCHEMBL18677725 | 0.81 | HDAC1 (0.30) | — | |
| SCHEMBL18950706 | 0.63 | HDAC1 (0.34) | — | |
| SCHEMBL23511351 | 0.62 | FAAH (0.53) | MAPTALDH1A1 | |
| SCHEMBL30945265 | 0.62 | MEN1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL23511352 | 0.62 | MEN1 (0.47) | MAPTALDH1A1HTT | |
| SCHEMBL31506950 | 0.61 | HDAC1 (0.34) | — | |
| SCHEMBL25044413 | 0.61 | FAAH (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028424-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190218592-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | PROMEGA CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-10240184-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20190085305-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2019-03-21 | — | — | US | disclosed |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-04-06 | — | — | US | disclosed |
| US-20170088877-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-03-30 | — | — | US | disclosed |
| US-9540402-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2017-01-10 | — | — | US | disclosed |
| US-9416353-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160031911-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-02-04 | — | — | US | disclosed |
| US-20150125924-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2015-05-07 | — | — | US | disclosed |
| US-7429472-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2008-09-30 | — | — | US | disclosed |
| US-7429472-B2 | Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule | PROMEGA CORPORATION | 2008-09-30 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425436-B2 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080026407-A1 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-20080026407-A1 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION | 2008-01-31 | — | — | US | disclosed |
| US-7238842-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-7238842-B2 | Covalent tethering of functional groups to proteins | PROMEGA CORPORATION (US) | 2007-07-03 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | PROMEGA CORPORATION | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088877-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | GGT1, HDHD5, DNPH1 | MAPT 4294/4885ALDH1A1 1284/4885SLC9A3 4305/4885 |
| US-20070087400-A1 | Covalent tethering of functional groups to proteins and substrates therefor | WASF2, NOTUM, YIPF5 | MAPT 4367/4885ALDH1A1 2110/4885SLC9A3 4163/4885 |
| US-20170097356-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS AND SUBSTRATES THEREFOR | WASF2, NOTUM, YIPF5 | MAPT 4367/4885ALDH1A1 2110/4885SLC9A3 4163/4885 |
| US-20190085305-A1 | METHOD OF IMMOBILIZING A PROTEIN OR MOLECULE VIA A MUTANT DEHALOGENASE THAT IS BOUND TO AN IMMOBILIZED DEHALOGENASE SUBSTRATE AND LINKED DIRECTLY OR INDIRECTLY TO THE PROTEIN OR MOLECULE | HDHD5, DDT, DDAH1 | MAPT 4393/4885ALDH1A1 690/4885SLC9A3 4251/4885 |
| US-20190218592-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | GGT1, HDHD5, DNPH1 | MAPT 4294/4885ALDH1A1 1284/4885SLC9A3 4305/4885 |
| US-11028424-B2 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | MAPT 4294/4885ALDH1A1 1284/4885SLC9A3 4305/4885 |
| US-20080026407-A1 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | MAPT 4294/4885ALDH1A1 1284/4885SLC9A3 4305/4885 |
| US-20160031911-A1 | COVALENT TETHERING OF FUNCTIONAL GROUPS TO PROTEINS | GGT1, HDHD5, DNPH1 | MAPT 4294/4885ALDH1A1 1284/4885SLC9A3 4305/4885 |
| US-10240184-B2 | Covalent tethering of functional groups to proteins | GGT1, HDHD5, DNPH1 | MAPT 4294/4885ALDH1A1 1284/4885SLC9A3 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.